Mar 28 |
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
|
Mar 27 |
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
|
Mar 27 |
AEterna Zentaris: Q4 Earnings Insights
|
Mar 27 |
Aeterna Zentaris reports Q4 results
|
Mar 27 |
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
|
Mar 12 |
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
|
Feb 26 |
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
|
Feb 15 |
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
|
Feb 15 |
Aeterna Zentaris files to sell 2.53M warrants
|
Dec 14 |
Aeterna Zentaris and Ceapro to merge in all-stock deal
|